'Lifechanging' migraine pill which slashes attacks by half set to be available in months

Logo Daily MailDaily Mail
2023-09-03 23:19:44  • 1 min

Millions of migraine sufferers could soon benefit from a new drug which has been found to reduce attacks by half.

Taken as a daily pill, trials of atogepant revealed it cut migraines from an average of eight to four a month double the success of current tablets.

The drug has been licensed by the Medicines and Healthcare products Regulatory Agency and experts predict it will soon be available to patients, pending a green light from the National Institute for Health and Care Excellence.

Known as a CGRP inhibitor, it works by blocking the effect of calcitonin gene-related peptide a protein known to trigger migraines.

Continue read on dailymail.co.uk

Astrazeneca shares rose after a positive trial of a drug for a common type of breast cancer. The study found datopotamab deruxtecan showed a 'statistically...
Logo Daily MailDaily Mail
2023-09-22 20:50:11  • 1 min
A woman has told how an operation to ease her husband's operation to ease his crippling migraines has been cancelled twice due to strikes by NHS medics....
The buzz among investors has been on the rise after a study showed obesity drug Wegovy reduced the risks of heart attacks and strokes.
Logo FortuneFortune
2023-09-22 21:19:39  • 1 min
By Philippa Roxby Health reporter A treatment for migraine attacks which dissolves under the tongue will soon be available on the NHS in what experts say is...
Logo BBCBBC
2023-09-14 00:09:55  • 1 min
AstraZeneca shares jumped on Friday after the group reported positive results in a breast cancer drug trial, in which an experimental drug slowed progression...
Logo Daily MailDaily Mail
2023-09-22 12:41:10  • 1 min
Fintel reports that on September 22, 2023, HC Wainwright & Co. maintained coverage of Travere Therapeutics ( NASDAQ:TVTX ) with a Buy recommendation....
Logo NasdaqNasdaq
2023-09-22 17:34:05  • 1 min
By Cara Murez HealthDay Reporter FRIDAY, Sept. 22, 2023 (HealthDay News) New research suggests some newer diabetes treatments may not be as beneficial for...
By Madeline Halpert BBC News, New York Rosa passes by Divino Nio Daycare every day on her way to work at her own childcare centre in the northern New York...
Logo BBCBBC
2023-09-23 00:15:46  • 1 min
On Tuesday, The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's SPRY New Drug Application (NDA) for neffy (epinephrine nasal spray)...
Logo BenzingaBenzinga
2023-09-21 19:38:12  • 1 min
Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for...
A TikTok user recently released a video of herself eating a lemon, explaining that it helped with her migraine pain. But doing so could actually cause the...
Logo The IndependentThe Independent
2023-09-19 20:21:11  • 1 min
Health care stocks were slightly higher late Friday afternoon with the NYSE Health Care Index up 0.1% and the Health Care Select Sector SPDR Fund (XLV)...
Logo NasdaqNasdaq
2023-09-22 19:48:37  • 1 min
Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals ( NASDAQ:AUPH ) with a Buy recommendation....
Logo NasdaqNasdaq
2023-09-22 21:51:00  • 1 min
(RTTNews) - Pulmatrix, Inc. (PULM) announced the FDA has accepted the PUR3100 investigational new drug application and the company has received a study may...
Logo NasdaqNasdaq
2023-09-19 13:21:17  • 1 min
From Sept. 10 to Sept. 15, Crinetics Pharmaceuticals (NASDAQ: CRNX) stock price gained 83%, and it's still climbing rapidly. The pre-revenue biotech's lead...
Logo NasdaqNasdaq
2023-09-19 13:11:54  • 1 min
(RTTNews) - Seagen Inc. (SGEN) and Astellas Pharma Inc. reported positive topline results from the Phase 3 EV-302 trial for PADCEV in combination with...
Logo NasdaqNasdaq
2023-09-22 09:51:30  • 1 min
In our modern age, the power of gene editing is undeniable. After years of foundational scientific research, it's now becoming possible to treat illnesses...
Logo NasdaqNasdaq
2023-09-23 12:45:00  • 1 min
Pirola may pose no more reason for concern than the swathe of other Covid variants that are spreading, UK Health Security Agency (UKHSA) scientists have...
As far as nightmare debuts go, not many will trump Folarin Balogun's disastrous first start for new club Monaco. The USMNT striker got his Monaco career...
Logo Daily MailDaily Mail
2023-09-22 22:54:32  • 1 min
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced positive 24-month results from the Phase 3 GATHER2 clinical trial evaluating the efficacy and...
Logo NasdaqNasdaq
2023-09-19 02:03:26  • 1 min